Guided Therapeutics (GTHP) Capital Expenditures Growth (1y) (2012 - 2022)
Guided Therapeutics (GTHP) Capital Expenditures Growth (1y) (2012 - 2022) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 108.71 Bn | 99.49 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.50 Bn | 67.05 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 48.59 Bn | 44.92 Bn | 1.29 Bn | 15.89% |
| 6 | Dexcom | 28.40 Bn | 27.29 Bn | 750.30 Mn | -11.95% |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 106.98% |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.50 Bn | 22.37 Bn | 2.07 Bn | -47.73% |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -90.32% |
| Sep 30, 2022 | 86.36% |
| Jun 30, 2022 | 325.00% |
| Mar 31, 2022 | 1,300.00% |
| Sep 30, 2021 | -29.41% |
| Jun 30, 2021 | -77.78% |
| Sep 30, 2018 | 128.09% |
| Mar 31, 2018 | -800.00% |
| Sep 30, 2017 | -1,395.00% |
| Mar 31, 2017 | 94.44% |
| Dec 31, 2016 | 683.33% |
| Sep 30, 2016 | -266.67% |
| Jun 30, 2016 | -350.00% |
| Mar 31, 2016 | -125.00% |
| Sep 30, 2015 | 107.02% |
| Jun 30, 2015 | 88.24% |
| Mar 31, 2015 | -300.00% |
| Sep 30, 2014 | -1,810.00% |
| Mar 31, 2014 | -96.04% |
| Dec 31, 2013 | 79.20% |